Dr. Bonaca, the Principal Investigator of VOYAGER PAD, revisits key findings from the trial and discusses implications for your Marc Bonaca MD specializes in Cardiology at UCHealth Heart and Vascular Center - Anschutz Medical Campus. Breakthrough Leg Cramp Drug For PAD Patients With Diabetes
Dr. Marc Bonaca, Associate Physician, Brigham & Women's Hospital 2.3.16. Join Dr. Marc Bonaca, renowned Interventional Cardiologist and Chairman of the American Heart Association PAD Collaborative,
Catheter Techniques Marc Bonaca's profile on LinkedIn, a professional community of 1 billion members Marc Bonaca. CPC Clinical Research Brigham and Women's Hospital. Denver
Investigator Marc Bonaca, MD, MPH reports the results of the VOYAGER PAD trial, which examined reducing the risk of adverse For more details you can visit our facebook page : facebook: or call our helpline
STICH Trial Analysis Marc Bonaca, MD. Professor, Medicine-Cardiology. Faculty Photo. Medical DR, Garcia LA, Kum SWC, Rundback J, Armstrong E, Lee JK, Khatib Y, Weinberg New Trials, New Therapies, and Some Old Challenges: An Interview with Marc Bonaca, MD
In today's podcast we are joined by Dr. Marc Bonaca to discuss the findings of the recent VOYAGER PAD trial and the use of Cleerly's new Cardiac Beat video series features conversations on the future of wholeheart™ care. In our first Cardiac Beat, ACC 2019: DECLARE TIMI 58 - Dr Marc P. Bonaca
Marc Bonaca, MD. Controversy in Vascular Care: STRIDE-PAD Findings Spark Heated Panel Debate
Marc P Bonaca, Cardiology | Radcliffe Cardiology Speakers: Drs. C. Michael Gibson and Marc Bonaca Drs. C. Michael Gibson and Marc Bonaca discuss updates and key Dr Marc P. Bonaca (University of Colorado School of Medicine, Aurora, Colorado, US) discusses DECLARE - TIMI 58
Vorapaxar and Peripheral Revascularization: More Than Purely Anti-Thrombotic Effects? The American College of Cardiology Scientific Sessions in Orlando, Florida, is full of new research. One of the worlds experts on
Marc P. Bonaca, MD, a professor of medicine and Director of Vascular Research at the University of Colorado, talks with DocWire Vorapaxar reduces peripheral revascularization in patients with PAD. In this interview, Marc Bonaca, MD, of the TIMI Study Group,
The Cardiac Beat: Cleerly Care Pathway Marc Peter Bonaca, MD, MPH, talks about Acute Aortic Syndrome and the importance of diagnosing and treating rapidly, as BWH
Struggling to walk as far as you used to? It might not be aging—it could be Peripheral Artery Disease (PAD), a dangerous Peter Block, MD, FACC, interviews Marc P. Bonaca, MD. Marc Bonaca - CPC Clinical Research | LinkedIn
How would you know if you had leg clots? || Dr Rajiv Parakh || Healthy Blood Vessels. Clot Chronicles: PAD Management-Key Insights from the VOYAGER PAD Trial
Emerging Role of Rivaroxaban Across the Atherothrombotic Disease Spectrum VOYAGER PAD | Marc Bonaca, MD, MPH Interview: Developments in Atherosclerotic Disease Treatment, COVID-19, and More
For the first time in over TWO DECADES, there's a new medication treatment approach for peripheral artery disease! Data Deep Dive: The Latest Insights from STRIDE-PAD and SOUL
Trouble Walking? Take Off Your Socks At the Doc! #shorts #viral marc.bonaca@cuanschutz.edu
ACC 2020: Primary Results Of The Voyager Pad Trial — Dr Marc P Bonaca Marc Bonaca MD MPH - Google Scholar Date: February 16, 2021 Presenters: Geoffrey Barnes, MD, MSc, Marc Bonaca, MD, MPH, Henry Han, MD, Eva Kline-Rogers, MS,
Marc Petter Bonaca, MD, MPH & Investigator in the TIMI Study Group discusses efficacy and safety of ticagrelor as long-term Stephen Crowley, M.D. discusses when Cardiologists use catheter techniques. To find out more information please visit our Dr. Marc Bonaca on the VOYAGER PAD Study
Marc Bonaca, MD | Profiles | School of Medicine | University of Rivaroxaban for Reducing Vascular Event Risks after Limb Revascularization for Peripheral Artery
Ticagrelor as Long-Term Secondary Prevention in Patients with PAD and Prior MI Dr. Marc P. Bonaca, MD, MPH, is a Cardiologist and Vascular Medicine Specialist who serves as the Executive Director of CPC Clinical Research and CPC Community Marc P. Bonaca, MD, MPH, FACC, FAHA • CPC Clinical Research
In the second part of this two-part interview, Marc Bonaca, MD, a professor of medicine and Director of Vascular Research at the In this clip from VIVA's recent Data Deep Dive, Dr. Marc Bonaca presents new findings from the STRIDE-PAD study, leading to a Marc P. Bonaca, MD, of Brigham and Women's Hospital and a member of the TIMI Study Group, talks with CSWN about stroke and
AHA 22: BT001 PIVOTAL: nCBT in Pts with Type II Diabetes | Dr Marc Bonaca Study PI Dr. Marc Bonaca presents VOYAGER results to VIVA board members in this roundtable conversation.
TRA 2°P-TIMI 50 Trial: New Stroke and Outcomes with Vorapaxar Antithrombotic Therapy for Long-Term Secondary PreventionClinical Challenges Dr. Marc Bonaca and I discussed the STRIDE trial. Semaglutide
Carolyn's and Marc's 40th Birthday Party Visit Radcliffe Cardiology: VIVA Explores VOYAGER Findings
Marc Bonaca MD - Peripheral Artery Disease New Data and New Guidelines Dr Marc Bonaca Discusses the Significance of VOYAGER-PAD Trial Findings in Cardiology Grand Rounds 3/31/2021
Walking as PAD Therapy Breakthrough Research of the Year | Global PAD Impact Awards VOYAGER, Atherosclerotic Disease, and More: An Interview with Marc Bonaca, MD
Co-authors. Deepak L. Bhatt, MD, MPH, MBADr. Valentin Fuster Professor of Cardiovascular Medicine, Icahn School of Medicine at PAD Treatment Breakthrough: Diabetes and Weight Loss Drug Reduces leg Pain
STICH was an important trial presented at the American College of Cardiology 2011 Scientific Session. Listen to primary results Data Deep Dive: SOUL Study Discussion Dr Marc P Bonaca (University of Colorado School of Medicine, Aurora, CO, US) shares the primary results of the Voyager Pad
Dr. Valentin Fuster talks with experts about the practice-changing elements from the VICTORIA and VOYAGER PAD trials. Marc Bonaca MD MPH (@MarcBonaca) / Posts / X
TRA2P TIMI 50 Trial in PAD by Dr. Marc Bonaca from Brigham and Women's Hospital, Boston, MA The STRIDE Trial: A New Dawn for Patients Living with PAD and Diabetes I've spent years telling the stories of peripheral artery In this new paper in JACC, Marc P. Bonaca, MD, of the TIMI Study Group, discusses new data from PEGASUS-TIMI 54. The CSWN
VOYAGER-PAD helps to underscore that peripheral artery disease is a different disease state than coronary disease and different January 25th, 2014 at Legal Seafood Harborside Roofdeck.
ACC 25 Late-Breaking Discussion: STRIDE: Semaglutide for Functional Capacity in Pts with T2D and PAD Marc P. Bonaca, MD, Professor of Medicine and Director of Vascular Research at the University of Colorado, provides some
Ticagrelor reduces risk of limb events in patients with CAD and T2D; Greater benefit in PAD. Title: Racial and regional disparities in the utilization of preventative care strategies among patients with peripheral artery disease
Late-Breaker host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by Dr Marc Bonaca (University of Chloe Wilson and Flavia Geraldes of The Lancet caught up with Professor Marc Bonaca and Professor Subodh Verma at ACC ESC 2020: The THEMIS-PAD Trial — Dr Marc P Bonaca
Dr Marc P Bonaca (University of Colorado, Aurora, CO, US) discusses the results of the THEMIS trial focusing on the A TIMI Risk Score for Stable Ischemic Heart Disease? FITsOnTheGo is an initiative led by the Mayo Clinic Rochester Cardiology Fellowship in collaboration with the ACC. Each year
Dr. Marc Bonaca and I discussed the STRIDE trial. Semaglutide improves functional outcomes in DM pts with symptomatic PAD, addressing a critical unmet need. Marc P. Bonaca, MD of the TIMI Study Group, discusses a new approach for assessing risk in patients with stable ischemic HD. ACC/AHA Aortic Disease Guidelines | AHA 2022
Marc Bonaca MD | Cardiology | UCHealth Late-breaking data from the STRIDE and SOUL studies show semaglutide improved symptoms, walking distance, and quality of Marc Bonaca MD. Professor. Cardiology (SOM). Email Address:marc.bonaca@cuanschutz.edu Find a Doctor · Clinical Trials. Partnerships. UCHealth University of
Dr. Marc Bonaca is a Cardiologist and Vascular Medicine Specialist who serves as the Executive Director of CPC Clinical Research and CPC Community Health. Marc Bonaca MD MPH Cardiology and Vascular Medicine Specialist. Executive Director of CPC Clinical Research. Director of Vascular Research. University of
Latest P2Y12 Inhibition Research from #ACC18 Dr Marc P. Bonaca is a cardiologist and vascular medicine specialist serving as Executive Director of the Colorado Prevention Center (CPC) and Director of
AHA 2015 | PEGASUS-TIMI 54 Trial Patients with PAD, prior MI benefit greatly from long-term ticagrelor therapy
VESS Winter Annual Meeting (Virtual) - Session 2, Talk 2 Marc Bonaca & Subodh Verma on the STRIDE trial #acc25 #cardiology Prof Marc p Bonaca on THEMIS-PAD
Marc Bonaca discusses the aims and key findings of the PEGASUS-TIMI 54 trial, and how they could be incorporated into clinical Peripheral Artery Disease and Dual Inhibition Therapy: Vascular Protection in Patients with CAD/PAD
ESC 2016 Dr Marc Bonaca Interview Acute Aortic Syndrome Video - Brigham and Women's Hospital Marc P. Bonaca, MD, MPH | Cardiometabolic Health Congress
The Global PAD Association is thrilled to announce Dr. Marc Bonaca and his research team as recipients of the "Walking As Marc P. Bonaca, MD, of the TIMI Study Group at Brigham and Women's Hospital in Boston, talks with CSWN about the results of
TRA 2°P-TIMI 50 Trial: Vorapaxar and Stent Thrombosis In this clip from VIVA's recent Data Deep Dive, Dr. Darren McGuire presents new findings from the SOUL study. Moderator: Joshua
Novel Antithrombotics and Antiplatelets in the Treatment of PAD ACC.20/WCC Virtual: Day 1 Cardiology Hour Why Your Walking Problems Could Be Poor Circulation Called PAD
Dr. Marc Bonaca and Dr. Shiavax Rao on Primary Results of the STRIDE Trial Title: Improving Outcomes in Peripheral Artery Disease: Stepping in the Right Direction Presenter: Marc P. Bonaca, MD, MPH,